MoonLake Immunotherapeutics Class A Ordinary Shares MLTX
Analyst Ratings
- Consensus
- Moderate Buy — 8 Buy · 1 Hold · 2 Sell (11 analysts)
- Avg. Price Target
- $30.55 (+147.5% upside)
Key Stats
- Today's Range
- $10.65 – $13.33
- 50-Day Range
- $9.46 – $17.73
- 52-Week Range
- $5.95 – $62.75
- Volume
- 6.12 million shs
- Average Volume
- 2.02 million shs
- Market Cap
- $906.39 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.05%
- Days to Cover
- 1.00
About MoonLake Immunotherapeutics Class A Ordinary Shares
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Related Stocks
Compare head-to-head: MLTX vs LLY·MLTX vs JNJ·MLTX vs ABBV·MLTX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.